Roctavian is an adeno-associated virus vector-based gene therapy that is administered as a single dose by intravenous infusion, according to a June 29 agency news release. It contains a viral vector carrying a gene for clotting, which is expressed in the liver to increase blood levels of factor VIII, a protein that enables blood clots, and reduces risk of uncontrolled bleeding.
In a trial of 112 patients with a three-year follow-up, the mean annual bleeding rate decreased from 5.4 bleeds per year to 2.6 bleeds.
Hemophilia A is a rare genetic bleeding disorder due to a mutation of the gene that produces factor VIII.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
